Transcatheter aortic valve implantation (TAVI), also called as transcatheter aortic valve replacement (TAVR), is a minimally invasive surgical procedure, which is performed to treat high-risk patients suffering from aortic stenosis.
Drivers & Restraints
The global market is anticipated to rise at a considerable rate during the forecast period. In the recent years, the market was growing at a steady rate and with the rising adoption of strategies by key players; the market is expected to rise over the projected horizon. The need of transcatheter aortic valve implantation is on the rise due to the increase in prevalence of aortic stenosis is boosting the market demand.
Sample Link Here: https://www.crystalmarketresearch.com/report-sample/HC0912782
The market has been segment into North America, South America, Europe, Asia-Pacific, and Middle East and Africa. South Africa is evolving in as one of the emerging nations that favour the growth of the transcatheter aortic valve implantation (TAVI) market.
Purchase Link Here: https://www.crystalmarketresearch.com/checkout/HC0912782
Boston Scientific Corporation (Symetis SA)
Bracco S.p.A. (HLT, Inc.)
Edwards Lifesciences Corporation
JenaValve Technology, Inc.
JC Medical, Inc.
Meril Life Sciences Pvt. Ltd.
NVT AG, and Venus Medtech, Inc.